SLC5A2 and aortic valve stenosis: Collectively, these findings unveil a previously underappreciated therapeutic axis wherein SGLT2 inhibitors may mitigate anemia-associated risk in AS through mechanisms distinct from volume contraction or hemoconcentration, with potential implications for improving myocardial oxygenation and delaying decompensation in this high-risk population.